Literature DB >> 21870266

Quantification of PARP activity in human tissues: ex vivo assays in blood cells and immunohistochemistry in human biopsies.

Eszter M Horvath1, Zsuzsanna K Zsengellér, Csaba Szabo.   

Abstract

Poly (ADP-ribosyl)ation of proteins is a posttranslational modification mediated by poly (ADP-ribose) polymerases (PARPs) that uses NAD(+) as substrate to form the negatively charged polymer of poly (ADP-ribose) (PAR). After DNA damage, PARP-1 is responsible for approximately 90% of the total cellular PARylation activity. Numerous studies showed activation of PARP-1 in various conditions associated with oxidative and nitrosative stress, such as ischemia-reperfusion injury, diabetes mellitus, and inflammation, and also proved the beneficial effects of PARP inhibitors. Pharmacological inhibitors of PARP move toward clinical testing for a variety of indications, including cardioprotection and malignant tumors. Some of the compounds are already in clinical trials. These advances necessitate the detection of PARP activation in human tissues. In the present chapter, we review specific methods used to detect PARP activation in human circulating leukocytes and human tissue sections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21870266      PMCID: PMC4666493          DOI: 10.1007/978-1-61779-270-0_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.

Authors:  Emese Tóth-Zsámboki; Eszter Horváth; Katarina Vargova; Eszter Pankotai; Kanneganti Murthy; Zsuzsanna Zsengellér; Tamás Bárány; Tamás Pék; Katalin Fekete; Róbert Gábor Kiss; István Préda; Zsombor Lacza; Domokos Gerö; Csaba Szabó
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

2.  Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.

Authors:  J M de Murcia; C Niedergang; C Trucco; M Ricoul; B Dutrillaux; M Mark; F J Oliver; M Masson; A Dierich; M LeMeur; C Walztinger; P Chambon; G de Murcia
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 3.  Poly(ADP-ribose): novel functions for an old molecule.

Authors:  Valérie Schreiber; Françoise Dantzer; Jean-Christophe Ame; Gilbert de Murcia
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

Review 4.  Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.

Authors:  Prakash Jagtap; Csaba Szabó
Journal:  Nat Rev Drug Discov       Date:  2005-05       Impact factor: 84.694

5.  The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes.

Authors:  Pal Pacher; Lucas Liaudet; Francisco Garcia Soriano; Jon G Mabley; Eva Szabó; Csaba Szabó
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

6.  Nitrative stress and poly(ADP-ribose) polymerase activation in healthy and gestational diabetic pregnancies.

Authors:  E M Horváth; R Magenheim; E Kugler; G Vácz; A Szigethy; F Lévárdi; M Kollai; C Szabo; Z Lacza
Journal:  Diabetologia       Date:  2009-07-14       Impact factor: 10.122

Review 7.  The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.

Authors:  László Virág; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

Review 8.  The PARP superfamily.

Authors:  Jean-Christophe Amé; Catherine Spenlehauer; Gilbert de Murcia
Journal:  Bioessays       Date:  2004-08       Impact factor: 4.345

9.  Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE.

Authors:  Y A Lazebnik; S H Kaufmann; S Desnoyers; G G Poirier; W C Earnshaw
Journal:  Nature       Date:  1994-09-22       Impact factor: 49.962

  9 in total
  5 in total

1.  PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations.

Authors:  Dimitrios E Kouzoukas; Jennifer A Schreiber; Nuzhath F Tajuddin; Simon Kaja; Edward J Neafsey; Hee-Yong Kim; Michael A Collins
Journal:  Neurochem Int       Date:  2019-06-25       Impact factor: 3.921

2.  Quantification of cellular poly(ADP-ribosyl)ation by stable isotope dilution mass spectrometry reveals tissue- and drug-dependent stress response dynamics.

Authors:  Rita Martello; Aswin Mangerich; Sabine Sass; Peter C Dedon; Alexander Bürkle
Journal:  ACS Chem Biol       Date:  2013-05-13       Impact factor: 5.100

3.  PARP-1 and SIRT-1 are Interacted in Diabetic Nephropathy by Activating AMPK/PGC-1α Signaling Pathway.

Authors:  Hengmei Zhu; Zhi Fang; Jiehui Chen; Yun Yang; Jiacheng Gan; Liang Luo; Xiaojiang Zhan
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-25       Impact factor: 3.168

4.  Reduced estradiol-induced vasodilation and poly-(ADP-ribose) polymerase (PARP) activity in the aortas of rats with experimental polycystic ovary syndrome (PCOS).

Authors:  Gabriella Masszi; Eszter Maria Horvath; Robert Tarszabo; Rita Benko; Agnes Novak; Anna Buday; Anna-Maria Tokes; Gyorgy L Nadasy; Peter Hamar; Zoltán Benyó; Szabolcs Varbiro
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 5.  Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.

Authors:  Dawid Sigorski; Ewa Iżycka-Świeszewska; Lubomir Bodnar
Journal:  Target Oncol       Date:  2020-12       Impact factor: 4.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.